Eseng Lai

机构：Merck & Co., Inc., Rahway, NJ, USA (United States) · ORCID：0000-0001-5141-3452

发表论文 97 篇 · 总被引 7277 次 · h-index 38

代表论文

• Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor (2023 · Circulation · 被引 168)
• Effects of an 11 β ‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome (2011 · Diabetes Obesity and Metabolism · 被引 162)
• A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults (2020 · Human Vaccines & Immunotherapeutics · 被引 154)
• Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression (2012 · Science Translational Medicine · 被引 127)
• A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus (2017 · Cardiovascular Diabetology · 被引 110)
• A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults (2020 · Clinical Pharmacology in Drug Development · 被引 67)